Algert Global LLC Acquires 39,235 Shares of Vera Therapeutics, Inc. $VERA

Algert Global LLC lifted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 15.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 293,388 shares of the company’s stock after acquiring an additional 39,235 shares during the period. Algert Global LLC owned 0.46% of Vera Therapeutics worth $8,526,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VERA. Deerfield Management Company L.P. increased its stake in Vera Therapeutics by 8.8% during the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after acquiring an additional 293,040 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Vera Therapeutics by 32.9% in the 3rd quarter. Two Sigma Investments LP now owns 171,659 shares of the company’s stock worth $4,988,000 after purchasing an additional 42,524 shares during the period. Soviero Asset Management LP boosted its holdings in shares of Vera Therapeutics by 233.3% in the 3rd quarter. Soviero Asset Management LP now owns 100,000 shares of the company’s stock worth $2,906,000 after purchasing an additional 70,000 shares during the period. Integral Health Asset Management LLC increased its position in shares of Vera Therapeutics by 47.8% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after purchasing an additional 550,000 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Vera Therapeutics by 57.5% during the 3rd quarter. UBS Group AG now owns 162,075 shares of the company’s stock valued at $4,710,000 after purchasing an additional 59,142 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

VERA stock opened at $40.05 on Tuesday. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $56.05. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -8.59 and a beta of 1.17. The business’s fifty day simple moving average is $43.67 and its two-hundred day simple moving average is $37.08. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter in the previous year, the firm earned ($0.72) EPS. Analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Wall Street Analyst Weigh In

VERA has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. The Goldman Sachs Group boosted their price objective on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Bank of America raised their target price on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Wedbush lifted their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $81.45.

Insiders Place Their Bets

In other Vera Therapeutics news, CFO Sean Grant sold 4,949 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $207,759.02. Following the transaction, the chief financial officer directly owned 114,181 shares in the company, valued at $4,793,318.38. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William D. Turner sold 2,187 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $91,810.26. Following the transaction, the insider directly owned 45,313 shares in the company, valued at approximately $1,902,239.74. This trade represents a 4.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 33,490 shares of company stock worth $1,405,910. 16.30% of the stock is owned by company insiders.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.